TAMPA, Fla., March 16, 2021 /PRNewswire-PRWeb/ — Smart Meter, makers of the iGlucose cellular-connected blood glucose monitoring system, today announced its partnership with PointClickCare, the leading cloud-based healthcare software for the long-term and post-acute care market. Through this partnership, care providers can now view patient blood glucose data in one Electronic Health Record (EHR) platform, eliminate manual glucose data entry or uploading, and reduce errors when using the iGlucose system during COVID-19. Smart Meter integrates with PointClickCare’s core EHR platform and will be listed as an integrated offering on the PointClickCare Marketplace.
Designed to capture real-time glucose results and enable customers a singular view of patient information, this collaboration is particularly important for remote patient management, a practice that has seen exponential growth as a result of desires to limit patient interactions during COVID-19.
“Over 30 percent of our residents have diabetes,” notes Clara Berry, Vice President of Clinical Services at Advanced Healthcare Solutions, LLC, headquartered in Arlington, Texas. “Since we initiated the use of the iGlucose system, our clinical providers have been excited to see the actual blood glucose results and trends for each patient in real-time, whether they are in the facility or working remotely. Now, with PointClickCare enterprise-wide integration, all patient information is visible on one secure platform for a more complete patient profile that allows for improved diabetes control.”
“Integration with PointClickCare elevates the iGlucose system to an entirely new level of implementation ease and standardization,” said Casey Pittock, Smart Meter CEO. “The iGlucose meter has always immediately transmitted data to the iGlucose portal via AT&T’s vast cellular network and now it seamlessly populates to the EMR, resulting in one repository for all patient parameters.”
Under recent Federal Drug Administration guidance, iGlucose meters can be used for individual patients residing in long-term care facilities during COVID-19. Benefits of using the iGlucose system include:
Additional information regarding the integration can be found on the PointClickCare Marketplace – an online platform that enables PointClickCare customers to easily evaluate authorized third-party technology partners. Partners listed on the PointClickCare Marketplace offer integrated apps and/or services that are designed to be quickly deployed and work seamlessly with a providers’ existing workflows.
To learn more about the iGlucose, iBloodPressure and other Smart Meter technologies, contact Smart Meter at 844-445-8267 or support@iglucose.com or visit SmartMeterRPM.com.
About Smart Meter, LLC
Smart Meter, LLC is a leading end-to-end solutions provider to businesses in the fast-growing telehealth and remote patient monitoring markets. Smart Meter’s proprietary cellular-connected medical devices, data transmission, and digital portals offer significant ease of use and cost advantages. The iGlucose and iBloodPressure systems are quickly becoming the platform of choice among emerging remote care companies and long-term care facilities. The patented iGlucose meter transmits real-time glucose results to a HIPAA-compliant cloud portal that provides trends, alerts, and formatted billing information. The accurate meter features a vibrant color screen, five-second test time, and needs only a tiny blood sample. Unlike devices requiring the use of smartphones, apps, Bluetooth, cables, or docking stations, iGlucose seamlessly and automatically transmits information with no user manipulation.
Media Contact
Jennifer Moritz, Smart Meter LLC, +1 (917) 748-4006, jmoritz@0to5.com
SOURCE Smart Meter LLC
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the…
LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of…
TUCSON, Ariz., Dec. 27, 2024 (GLOBE NEWSWIRE) -- via IBN – WEED Inc. (OTCQB: BUDZ), (“WEED,”…
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”),…
VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP…
Wuxi, China, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (the…